Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.

ABSTRACT:

Background

Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit.

Objective

To identify molecular features predictive of patient response to 5-ARIs.

Design, setting, and participants

Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed. Cross-species computational analyses were used to compare expression profiles for treated mice with those of patients who had received 5-ARIs before prostatectomy.

Intervention

Finasteride administered to Nkx3

SUBMITTER: Dutta A 

PROVIDER: S-EPMC5600823 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature